EN DE
Watch Jeonjinbio Co. Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Jeonjinbio Co. Ltd (110020) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Jeonjinbio Co. Ltd stock KRW 1,832, price KRW 2,000, that is 8.4% below the price, quality 39 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials KR · ISIN KR7110020005

JC Jeonjinbio Co. Ltd logo Thin data Nov 16, 2026

Jeonjinbio Co. Ltd

110020 · KQ

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Fair value 1,832 KRW · Fairly valued 
Expensive Growth (revenue 5y +28.8 %/yr in KRW) 
Revenue last quarter 19% below a year ago. 
Quality 39/100 
Falling price (downtrend) 
Loss-making · -2.2% net margin (TTM) 
Negative free cash flow 
Trails peers (4/11) 
Narrow moat 15/100
Thin data 
⟳ CyclicalEstimate
Watch Jeonjinbio Co. Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

9,800 KRW 1,641 KRW Fair Value 1,832 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 1,641 KRW – 9,800 KRW · fair‑value band 1,374 KRW – 2,291 KRW · the 2,000 KRW price screens above the 1,832 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Jeonjinbio Co. in your weekly email

Every Wednesday you see whether Jeonjinbio Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jeonjinbio Co., Ltd. develops and produces natural bio-pesticides, alternative chemical products, and other biotechnology products.

Show moreShow less

The company offers repellent for bird, boar, rodent, snake, and sea lice; and dress perfume, including Paris 16e, Paris 16e Bouquet, Bouquet Garni, and Bridcan, as well as mosquito repellent. It also provides laundry products.

Jeonjin Bio Co., Ltd. was founded in 2004 and is headquartered in Daegu, South Korea.

Stock analysis

Jeonjinbio Co. Ltd (110020) currently trades at 2,000 KRW, while our estimate is 1,832 KRW, so the stock looks roughly fairly valued today (gap 9.2%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,374 KRW (bear) to 2,291 KRW (bull), the price of 2,000 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Basic Materials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Jeonjinbio Co. Ltd reported revenue of 13.7B KRW in FY2025 versus 3.2B KRW in FY2021, a compound +43.7%/yr. Reported net income was −196M KRW in FY2025.

Key figures

Market cap 18.1B KRW (≈ $13.6M) Micro · P/S ratio 1.34 · EPS (TTM) −33.89 KRW · Net margin −2.2% · Return on equity −1.8% · Return on assets (EBIT) −7.3% (5-year average) · Operating margin −8.9% · Revenue (TTM) 13.7B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (medium confidence).

What moves the price

The share trades about 34% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at −8%, 110020 screens cheaper than that median.

Fair Value

Bear 1,374 KRW Fair Value 1,832 KRW Bull 2,291 KRW
Price 2,000 KRW · Downside -8.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 24
How much profit the company makes from its sales and capital
Quality Growth 2
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 96
Debt, balance sheet and risk of trouble
Investment 58
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−28.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.8%
Start year 2020 (pandemic). Over 10 years: +21.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−56.0% (2020) → −2.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 110020, get fair value alerts →

Compare Jeonjinbio Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 767 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −8.4% · Above median
Profitability
Return on assets −1.1% · Bottom 25%
Net margin (12 months) −2.2% · Bottom 25%
Operating margin (12 months) −8.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −19.4% · Bottom 25%

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/B 1.04× · Cheaper than median
P/S (12 months) 1.32× · Cheaper than median
EV/EBITDA 83.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 7
FUTURE (revenue growth)0 · sector 69
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wanhua Chemical Group 600309 ¥69.50 ¥68.03 −2% vs 110020
Linde plc LIN $512.16 $446.62 −13% vs 110020
PPG Industries, Inc PPG $122.78 $77.68 −37% vs 110020
DSM-Firmenich AG DSFIR CHF 96.85 CHF 58.32 −40% vs 110020
Asian Paints Limited ASIANPAINT ₹2,595 ₹1,479 −43% vs 110020
The Sherwin-Williams Company SHW $346.60 $152.59 −56% vs 110020
Givaudan SA GIVN CHF 4,054 CHF 1,618 −60% vs 110020
EMS-CHEMIE HOLDING AG EMSN CHF 830.50 CHF 284.63 −66% vs 110020
Ecolab Inc ECL $300.68 $97.18 −68% vs 110020
Air Products and Chemicals, Inc APD $308.11 $75.33 −76% vs 110020

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jeonjinbio Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jeonjinbio Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/110020

Frequently asked questions

Is Jeonjinbio Co. Ltd (110020) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 1,832 KRW versus a price of 2,000 KRW, about 8% lower (fairly valued).
What is the fair value of 110020?
Our estimate for Jeonjinbio Co. Ltd is 1,832 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 2,000 KRW.
What is the quality score of 110020?
Jeonjinbio Co. Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jeonjinbio Co. Ltd (110020)?
We do not set a price target; the yardstick is our estimate of 1,832 KRW (as of Nov 16, 2026). Cautious scenario 1,374 KRW, optimistic scenario 2,291 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Jeonjinbio Co. Ltd stock forecast for 2026?
Our estimate puts fair value at 1,832 KRW, about 8% lower versus a price of 2,000 KRW (fairly valued). Cautious scenario 1,374 KRW, optimistic scenario 2,291 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Jeonjinbio Co. Ltd (110020)?
Jeonjinbio Co. Ltd reported trailing-twelve-month revenue of about 13.7B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Jeonjinbio Co. Ltd (110020)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jeonjinbio Co. Ltd it is 1,832 KRW per share (as of Nov 16, 2026), against a price of 2,000 KRW.
Is Jeonjinbio Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 110020 trades above its calculated fair value: price 2,000 KRW, fair value 1,832 KRW, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 110020?
No. The price is what the market pays today (2,000 KRW); the fair value is what the company's own numbers justify (1,832 KRW). For Jeonjinbio Co. Ltd the two are 167.58 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Jeonjinbio Co. Ltd worth?
The market values Jeonjinbio Co. Ltd at about 18.1B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 2,000 KRW; our models calculate a fair value of 1,832 KRW per share.
What do the bullish and bearish scenarios say about 110020?
Our models span a range for Jeonjinbio Co. Ltd: cautious scenario 1,374 KRW, base 1,832 KRW, optimistic 2,291 KRW per share (as of Nov 16, 2026, price 2,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jeonjinbio Co. Ltd (110020)?
Balance-sheet figures for Jeonjinbio Co. Ltd (as of Nov 16, 2026): return on equity −1.8%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 110020 from its 52-week high?
Jeonjinbio Co. Ltd trades at 2,000 KRW, about 34% below its 52-week high of 3,020 KRW and 22% above the low of 1,641 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 1,832 KRW is for.
Which stocks are comparable to Jeonjinbio Co. Ltd?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jeonjinbio Co. Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price 2,000 KRW, calculated fair value 1,832 KRW (−8%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Jeonjinbio Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jeonjinbio Co. Ltd (110020)?
The closing price on Nov 19, 2026 was 2,000 KRW. Our estimate is 1,832 KRW, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jeonjinbio Co. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Jeonjinbio Co. Ltd

How large is the market capitalisation of Jeonjinbio Co. Ltd (110020)?
The market capitalisation of Jeonjinbio Co. Ltd is 18.1B KRW (≈ $13.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jeonjinbio Co. Ltd (110020)?
The price-to-sales ratio of Jeonjinbio Co. Ltd is 1.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jeonjinbio Co. Ltd (110020)?
Earnings per share at Jeonjinbio Co. Ltd are −33.89 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Jeonjinbio Co. Ltd (110020)?
The net margin of Jeonjinbio Co. Ltd is −2.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jeonjinbio Co. Ltd (110020)?
The return on equity (ROE) of Jeonjinbio Co. Ltd is −1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jeonjinbio Co. Ltd (110020)?
On an EBIT basis the return on assets of Jeonjinbio Co. Ltd is −7.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jeonjinbio Co. Ltd (110020)?
The operating margin of Jeonjinbio Co. Ltd is −8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jeonjinbio Co. Ltd (110020)?
Revenue at Jeonjinbio Co. Ltd is down 19.4% versus a year earlier (3y avg +20.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jeonjinbio Co. Ltd (110020)?
Earnings per share at Jeonjinbio Co. Ltd are down 40.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jeonjinbio Co. Ltd (110020) generate?
The free cash flow of Jeonjinbio Co. Ltd is −308M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jeonjinbio Co. Ltd (110020) carry?
The net debt of Jeonjinbio Co. Ltd is 3.6B KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Jeonjinbio Co. Ltd in the live analysis

One click puts Jeonjinbio Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.